Initial Statement of Beneficial Ownership (3)
May 05 2023 - 5:50PM
Edgar (US Regulatory)
FORM 3
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0104
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
TANG KEVIN C |
2. Date of Event Requiring Statement (MM/DD/YYYY)
5/3/2023
|
3. Issuer Name and Ticker or Trading Symbol
TCR2 THERAPEUTICS INC. [TCRR]
|
(Last)
(First)
(Middle)
4747 EXECUTIVE DRIVE, SUITE 210, |
4. Relationship of Reporting Person(s) to Issuer (Check all applicable)
_____ Director ___X___ 10% Owner _____ Officer (give title below) _____ Other (specify below)
|
(Street)
SAN DIEGO, CA 92121
(City)
(State)
(Zip)
| 5. If Amendment, Date Original Filed(MM/DD/YYYY)
| 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Beneficially Owned
|
1.Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
Common Stock | 3926287 | I | By LP (1) |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 4) | 2. Date Exercisable and Expiration Date (MM/DD/YYYY) | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Explanation of Responses: |
(1) | The shares are beneficially owned by Tang Capital Partners, LP ("TCP"). Kevin Tang is the sole manager of Tang Capital Management, LLC ("TCM"), which is the general partner of TCP. Mr. Tang has a pecuniary interest in the shares beneficially held by TCP. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
TANG KEVIN C 4747 EXECUTIVE DRIVE, SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
TANG CAPITAL MANAGEMENT LLC 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
TANG CAPITAL PARTNERS LP 4747 EXECUTIVE DRIVE SUITE 210 SAN DIEGO, CA 92121 |
| X |
|
|
Signatures
|
Kevin Tang | | 5/5/2023 |
**Signature of Reporting Person | Date |
Kevin Tang, Manager | | 5/5/2023 |
**Signature of Reporting Person | Date |
Kevin Tang, Manager of Tang Capital Management, LLC, General Partner | | 5/5/2023 |
**Signature of Reporting Person | Date |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
Note: | File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. |
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Aug 2024 to Sep 2024
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Sep 2023 to Sep 2024
Real-Time news about TCR2 Therapeutics Inc (NASDAQ): 0 recent articles
More Tcr2 Therapeutics Inc. News Articles